Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Brief Summary: The overall objective of this study is to assess efficacy and safety of 12 weeks, once daily, orally inhaled co-administration of olodaterol 5 µg (delivered by the Respimat® Inhaler) and tiotropium (delivered by the Handihaler® as Spiriva Handihaler®), compared to tiotropium (Spiriva Handihaler®) monotherapy on lung function in patients with COPD.


Options:
A: Arm Label: tiotropium+olodaterol low dose; Type: EXPERIMENTAL; Interventions: Device: Respimat inhaler, Drug: tiotropium+olodaterol (low dose) | Arm Label: tiotropium+olodaterol high dose; Type: EXPERIMENTAL; Interventions: Drug: tiotropium + olodaterol (high dose), Device: Respimat inhaler | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Device: Respimat inhaler, Drug: placebo to tiotropium+olodaterol | Intervention Type: DEVICE; Name: Respimat inhaler; Assigned to Arm(s): tiotropium+olodaterol low dose | Intervention Type: DRUG; Name: tiotropium+olodaterol (low dose); Assigned to Arm(s): tiotropium+olodaterol low dose | Intervention Type: DRUG; Name: tiotropium + olodaterol (high dose); Assigned to Arm(s): tiotropium+olodaterol high dose | Intervention Type: DEVICE; Name: Respimat inhaler; Assigned to Arm(s): tiotropium+olodaterol high dose | Intervention Type: DEVICE; Name: Respimat inhaler; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: placebo to tiotropium+olodaterol; Assigned to Arm(s): placebo
B: Arm Label: Olodaterol and Tiotropium; Type: EXPERIMENTAL; Interventions: Drug: Olodaterol, Drug: Tiotropium | Arm Label: Placebo and Tiotropium; Type: OTHER; Interventions: Drug: Tiotropium, Drug: Placebo matching Olodaterol | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Placebo and Tiotropium | Intervention Type: DRUG; Name: Placebo matching Olodaterol; Assigned to Arm(s): Placebo and Tiotropium | Intervention Type: DRUG; Name: Olodaterol; Assigned to Arm(s): Olodaterol and Tiotropium | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Olodaterol and Tiotropium
C: Intervention Type: DRUG; Name: Budesonide/formoterol pMDI; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Formoterol Turbuhaler; Assigned to Arm(s): N/A
D: Arm Label: QVA149; Type: EXPERIMENTAL; Interventions: Drug: indacaterol and glycopyrronium (QVA149), Drug: Placebo to fluticasone/salmeterol | Arm Label: fluticasone/salmeterol; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluticasone/salmeterol, Drug: Placebo to indacaterol and glycopyrronium (QVA149) | Intervention Type: DRUG; Name: indacaterol and glycopyrronium (QVA149); Assigned to Arm(s): QVA149 | Intervention Type: DRUG; Name: Placebo to fluticasone/salmeterol; Assigned to Arm(s): QVA149 | Intervention Type: DRUG; Name: fluticasone/salmeterol; Assigned to Arm(s): fluticasone/salmeterol | Intervention Type: DRUG; Name: Placebo to indacaterol and glycopyrronium (QVA149); Assigned to Arm(s): fluticasone/salmeterol

Answer: B